Jose-Carlos  Gutierrez-Ramos net worth and biography

Jose-Carlos Gutierrez-Ramos Biography and Net Worth

SVP of Danaher
Jose-Carlos (“JC”) is Senior Vice President and Chief Science Officer of Danaher. In this role, JC is responsible for setting Danaher’s science and technology strategy, supporting M&A and open innovation, and counseling Danaher’s operating companies on innovation opportunities. He leads the Danaher Innovation Centers and the Danaher Scientific Advisory Board. Working with technical leaders across Danaher, JC enables innovation best practice sharing and culture building.

“Science and technology is a powerful motivator for me and for many Danaher associates. We get up each day with a passion and goal to help solve our customers’ most complex challenges. Looking ahead the next five to ten years, we see tremendous opportunity to improve human health through scientific research and discovery.”

JC has diverse leadership experience across multiple biotech start-ups and pharmaceutical companies and deep expertise in translating new areas of science and technology into successful drug discovery and development programs and marketed drugs. Prior to Danaher, JC served as Global Head of Drug Discovery at AbbVie, Group SVP Biotherapeutics R&D at Pfizer and SVP and CEDD Head of Inmuno Inflammation at GlaxoSmithKline. JC was the founding CEO and President at Repertoire Immune Medicine where he built and led a team to decode the human immunome. Previously, he was President and CEO of Synlogic, where he led the company from early discovery to the clinical stage and to the public markets. In these global positions, he oversaw multiple drug discovery teams, resulting in five marketed drugs.

JC has a Ph.D. in immunology from the Universidad Autonoma de Madrid and trained as an immunologist in Spain, Germany and Switzerland. He started his academic career as Assistant Professor of Genetics at Harvard Medical School. He has authored more than 150 peer-reviewed publications.

What is Jose-Carlos Gutierrez-Ramos' net worth?

The estimated net worth of Jose-Carlos Gutierrez-Ramos is at least $1.69 million as of August 21st, 2023. Dr. Gutierrez-Ramos owns 6,939 shares of Danaher stock worth more than $1,689,924 as of July 21st. This net worth approximation does not reflect any other investments that Dr. Gutierrez-Ramos may own. Additionally, Dr. Gutierrez-Ramos receives an annual salary of $2,090,000.00 as SVP at Danaher. Learn More about Jose-Carlos Gutierrez-Ramos' net worth.

How old is Jose-Carlos Gutierrez-Ramos?

Dr. Gutierrez-Ramos is currently 62 years old. There are 7 older executives and no younger executives at Danaher. The oldest executive at Danaher is Mr. Steven M. Rales, Co-Founder & Chairman, who is 73 years old. Learn More on Jose-Carlos Gutierrez-Ramos' age.

What is Jose-Carlos Gutierrez-Ramos' salary?

As the SVP of Danaher Co., Dr. Gutierrez-Ramos earns $2,090,000.00 per year. There are 3 executives that earn more than Dr. Gutierrez-Ramos. The highest earning executive at Danaher is Mr. Rainer M. Blair, President, CEO & Director, who commands a salary of $5,330,000.00 per year. Learn More on Jose-Carlos Gutierrez-Ramos' salary.

How do I contact Jose-Carlos Gutierrez-Ramos?

The corporate mailing address for Dr. Gutierrez-Ramos and other Danaher executives is 2200 PENNSYLVANIA AVE. N.W SUITE 800W, WASHINGTON DC, 20037. Danaher can also be reached via phone at (202) 828-0850 and via email at [email protected]. Learn More on Jose-Carlos Gutierrez-Ramos' contact information.

Has Jose-Carlos Gutierrez-Ramos been buying or selling shares of Danaher?

Jose-Carlos Gutierrez-Ramos has not been actively trading shares of Danaher during the past quarter. Most recently, Jose-Carlos Gutierrez-Ramos sold 590 shares of the business's stock in a transaction on Monday, August 21st. The shares were sold at an average price of $250.54, for a transaction totalling $147,818.60. Following the completion of the sale, the senior vice president now directly owns 6,939 shares of the company's stock, valued at $1,738,497.06. Learn More on Jose-Carlos Gutierrez-Ramos' trading history.

Who are Danaher's active insiders?

Danaher's insider roster includes Rainer Blair (EVP), Daniel Comas (EVP), Georgeann Couchara (SVP), William Daniel (EVP), Brian Ellis (SVP), Linda Filler (Director), Jose-Carlos Gutierrez-Ramos (SVP), Linda Hefner (Director), Jennifer Honeycutt (EVP), Thomas Joyce, Jr. (CEO), William King (SVP), Angela Lalor (SVP), Angela Lalor (SVP), Teri List (Director), Walter Lohr (Director), Robert Lutz (CAO), Matthew McGrew (CFO), Mitchell Rales (Chairman), Daniel Raskas (SVP), John Schwieters (Director), Alan Spoon (Director), Raymond Stevens (Director), Joakim Weidemanis (EVP), and Elias Zerhouni (Director). Learn More on Danaher's active insiders.

Are insiders buying or selling shares of Danaher?

In the last twelve months, insiders at the conglomerate sold shares 16 times. They sold a total of 229,662 shares worth more than $58,354,751.67. The most recent insider tranaction occured on May, 16th when CEO Rainer Blair sold 9,005 shares worth more than $2,386,325.00. Insiders at Danaher own 11.1% of the company. Learn More about insider trades at Danaher.

Information on this page was last updated on 5/16/2024.

Jose-Carlos Gutierrez-Ramos Insider Trading History at Danaher

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/21/2023Sell590$250.54$147,818.606,939View SEC Filing Icon  
5/1/2023Sell500$242.19$121,095.007,529View SEC Filing Icon  
See Full Table

Jose-Carlos Gutierrez-Ramos Buying and Selling Activity at Danaher

This chart shows Jose-Carlos Gutierrez-Ramos's buying and selling at Danaher by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Danaher Company Overview

Danaher logo
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.
Read More

Today's Range

Now: $243.54
Low: $241.00
High: $245.25

50 Day Range

MA: $254.76
Low: $239.25
High: $267.98

2 Week Range

Now: $243.54
Low: $182.09
High: $269.11

Volume

2,982,627 shs

Average Volume

3,074,608 shs

Market Capitalization

$180.39 billion

P/E Ratio

41.28

Dividend Yield

0.44%

Beta

0.83